J Clin Oncol. 2022 Dec 6:JCO2200332. doi: 10.1200/JCO.22.00332. Online ahead of print.
NO ABSTRACT
PMID:36473143 | DOI:10.1200/JCO.22.00332
Categories
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651
